William Williams, CEO and Director, acquired 645,600 Common Shares on a direct ownership basis at a price of $0.140 through a private transaction on March 19th, 2018. The insider also acquired 645,600 Warrants with an exercise price of $0.100 for 36 months. This represents a $90,384 investment into the company's shares and an account share holdings change of 6.0%.
On the same terms, Rahoul Sharan, a Director, acquired 500,000 Common Shares and 500,000 Warrants on a direct ownership basis. This represents a $70,000 investment into the company's shares and an account share holdings change of 48.1%. Saeid Babaei, a Director, acquired 150,000 Common Shares and 150,000 Warrants on a direct ownership basis. This represents a $21,000 investment into the company's shares and an account share holdings change of greater than 100%.
BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Briacell Therapeutics Corp is a Canada-based clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The Company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT, in advanced breast cancer along with the co-development of BriaDX, its companion diagnostic. Additionally, there is a Food and Drug Administration (FDA) approved combination study of Bria-IMT with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT. Moreover, the Company is developing Bria-OTS, the first off the shelf personalized treatment for advanced stage breast cancer. Briacell Therapeutics Corp's small molecule program consists of novel, selective protein kinase C delta inhibitors that have shown activity in pre-clinical models of several cancers and fibrotic diseases.
No Comments